4 Therapies|Clear filters
Arsenic trioxide (2)
Reg. name: Trisenox
The mechanism of action of Arsenic Trioxide (ATO) has not been fully elucidated. However, Kamran Alimoghaddam1 has reported that ATO has induced differentiation in the NB4 cell line. In addition, the TRISENOX® summary of product characteristics states that ATO also causes damage or degradation of the fusion protein Pro-Myelocytic Leukemia/Retinoic Acid Receptor-α (PML/RAR-α).2
- Alimoghaddam K. A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia. Int J Hematol Oncol Stem Cell Res. 2014 Jul 1; 8(3): 44–54.
- TRISENOX® Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/28860. [Accessed January 2017].
TRISENOX® is indicated for induction of remission, and consolidation in adult patients with Relapsed/Refractory Acute Promyelocytic Leukemia (APL) (Previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.
TRISENOX® is indicated for induction of remission, and consolidation in adult patients with Newly diagnosed low-to-intermediate risk Acute Promyelocytic Leukemia (APL) (white blood cell count, ≤ 10 x 103/µl) in combination with All-Trans-Retinoic Acid (ATRA)
Reg. name: Vidaza
Class: Hypomethylating agent
The Summary of Product Characteristics for Vidaza® states that the antineoplastic effects of azacitidine are thought to be achieved through various mechanisms. These include a cytotoxic effect on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. In addition, inhibition of DNA, RNA, and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways.
- Vidaza® Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/21508. [Accessed January 2017].
VIDAZA® is indicated for the treatment of adult patients who are not eligible for Haematopoietic Stem Cell Transplantation (HSCT) with Acute Myeloid leukemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification